cas 85175-59-3, (Z)-3-(3-chloropropyl)-7,8-diethyl-1H-benzo[d] azepin-2 (3H)-one

Articles about 85175-59-3Total 13 be found

Article title
Article abstract
Author
Journal number and time
Download

AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
: Disclosed herein is an improved process for the preparation of Ivabradine and pharmaceutically acceptable salts thereof. The invention more particularly disclosesthe synthesis of key intermediates viz.,(S)-N-[(4,5-dimethoxybenzocydobut-l-yl)-methyl]-N- (methyl)amine hydrochloride of Formula-II and 3-(3-Iodopropyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzapin-2-one of Formula-III, and its use in industrial synthesis of Ivabradine and pharmaceutically acceptable salts thereof.
-
Page/Page column 19

(2019/11/12)

Synthetic method of ivabradine
The invention provides a synthetic method of ivabradine. The synthetic method of ivabradine comprises following steps: 1, a compound II and bromo chloropropane are subjected to alkylation reaction under the catalytic effect of a first alkali so as to obtain a compound III; 2, the compound III is subjected to hydrogenation reaction in a palladium on carbon and ammonium formate system so as to obtain a compound IV; 3, the compound IV and an iodination reagent are subjected to iodization reaction so as to obtain a compound V; 4, the compound V and the compound VI are subjected to condensation reaction under the catalytic effect of a second alkali so as to obtain a compound I. Operation is simple; reaction conditions are mild; the raw materials are commercially available; the synthetic methodis simple; cost is low; and the ivabradine synthesis difficulty is reduced greatly.
-
Paragraph 0014; 0037; 0038; 0042; 0043

(2018/06/21)

PROCESS FOR THE PREPARATION OF BENZAZEPINE-2-ONE DERIVATIVE
The present, invention relates to a cost effective, environment friendly industrially viable process for the preparation of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepine-2-one, an intermediate used in the preparation of ivabradine, without using acid chloride intermediate and condensing agent.
-
Page/Page column 15

(2017/09/05)

PROCESS FOR PREPARATION OF IVABRADINE
A process for the preparation of ivabradine pharmaceutically acceptable salts is disclosed. An amorphous form of ivabradine hydrochloride and a process for the preparation of it are also provided.
-
Paragraph 0120

(2014/07/21)

IVABRADINE HYDROCHLORIDE AND THE PROCESSES FOR PREPARATION THEREOF
The present disclosure relates to a process of preparing Ivabradine Hydrochloride, which is devoid of product related impurities. More specifically, the present disclosure provides a process to obtain a new polymorph of Ivabradine Hydrochloride, wherein said polymorph is pure and devoid of impurities at particular RRTs. The disclosure further relates to the removal of specific impurities of Formula 8 and/or Formula 9 during the preparation of said Ivabradine Hydrochloride. The disclosure also specifically provides the said polymorphic form of Ivabradine Hydrochloride.
-
Page/Page column 12; 13

(2014/02/16)

Synthesis and biological activity of some 1,3-dihydro-2H-3-benzazepin-2- ones with a piperazine moiety as bradycardic agents
A series of 1,3-dihydro-2H-3-benzazepin-2-ones with a piperazine moiety were designed and synthesized by treating the common intermediate of 1,3-dihydro-7,8-dimethoxy-3-[3-(1-piperazinyl)-propyl]-2H-3-benzazepin-2-ones with a variety of N-aryl-2-chloroacetamides and acyl chlorides. Their structures have been characterized by 1H-NMR, MS, and elemental analysis. The title compounds were evaluated for their bradycardic activity in vitro. Most of the synthesized compounds exhibited some vasorelaxant activity and heart-rate-reducing activity with bradycardic potency.
Liang, Hong-Yu,Zhang, Deng-Qing,Yue, Yun,Shi, Zhe,Zhao, Sheng-Yin
experimental part
p. 114 - 119
(2010/06/13)

PROCESS FOR PREPARATION OF IVABRADINE
The present invention describes a new process for optical resolution of [N-[[3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methylamine] which is an intermediate in the preparation of ivabradine.
-
Page/Page column 18-19

(2010/07/09)

(Benzocycloalkyl) alkylamines
The compounds are 3-[ (benzocycloalkyl)alkyl amino alkyl] -1,3,4,5-te trahydro 2H- 3-benzazepin-2 ones useful in cardiovascular field.A compound disclosed is (R,S)-7,8-dimethoxy-3-{3-{N-[(4,5-dimethoxybenzocyclobut-1-yl) methyl]-N-methyl amino}propyl}-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one.
-
(2008/06/13)

Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties
Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibition. The prototype falipamil (2) has been submitted to furthr optimization mainly hy manipulation of the phthalimidine moiety. This has resultd in a secod generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepione ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.
Reiffen,Eberlein,Muller,Psiorz,Noll,Heider,Lillie,Kobinger,Luger
p. 1496 - 1504
(2007/10/02)

(2H)-3-benzazepin-2-ones, their pharmaceutical compositions and their pharmaceutical uses
The invention relates to new heteroaromatic amine derivatives of formula STR1 wherein A represents a --CH2 --CH2 --, --CH=CH--or STR2 group and B represents a methylene, carbonyl or thiocarbonyl group or A represents a --CO--CO or STR3 group and B represents a methylene group, in which the carbon atom marked x is linked to the phenyl nucleus, E represents a straight-chained alkylene group optionally substituted by an alkyl group, G represents a straight-chained alkylene group optionally substituted by an alkyl group, R1 represents a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, nitro, amino, alkylamino, dialkylamino, alkyl, alkylmercapto, hydroxy, alkoxy or phenylalkoxy group, R2 represents a hydrogen, chlorine or bromine atom or a hydroxy, alkoxy, phenylalkoxy or alkyl group or R1 and R2 together represent an alkylenedioxy group, R3 represents a hydrogen atom, an alkenyl group, an alkyl or phenylalkyl group, and Het represents a 5- or 6-membered heteroaromtic ring bonded via a carbon or nitrogen atom, which contains an oxygen, sulphur or nitrogen atom, two nitrogen atoms or a nitrogen atom and an oxygen or sulphur atom, and onto which additionally a phenyl ring can be condensed, in which case the bond can also be via the phenyl nucleus, or an imidazo[1,2-a]pyridyl group wherein the carbon structure of the above-mentioned groups can be substituted by a methylenedioxy or ethylenedioxy group or can be mono- or disubstituted by a halogen atom or an alkyl, hydroxy, alkoxy, phenylalkoxy, phenyl, dimethoxyphenyl, nitro, amino, acetylamino, carbamoylamino, N-alkyl-carbamoylamino, hydroxymethyl, mercapto, alkylmercapto, alkylsulphinyl, alkylsulphonyl, alkylsulphonyloxy, alkylsulphonylamino, alkoxycarbonylmethoxy, carboxymethoxy or alkoxymethyl group, and at the same time any imino group present in the above-mentioned heteroaromatic groups can be substituted by an alkyl, phenylalkyl or phenyl group, the N-oxides and the acid addition salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly the effect of lowering heart rate and oxygen requirement of the heart. They can be used to treat sinus tachycardia or ischaemic heart disease.
-
(2008/06/13)

Benzazepine derivatives
This invention relates to benzazepine derivatives of formula I STR1 wherein A is --CH2 CH2 -- or --CH=CH--; R1 is hydrogen, chlorine, bromine, C1 -C3 alkyl, amino, C1 -C3 alkylamino, C1 -C3 dialkylamino, acylamino, hydroxy, C1 -C3 alkoxy or phenyl C1 -C3 alkoxy; R2 is hydrogen, chlorine, bromine, hydroxy, C1 -C3 alkyl, C1 -C3 alkoxy or phenyl C1 -C3 alkoxy or, together with R1, can be C1 -C3 alkylenedioxy; R3 is hydrogen, chlorine, bromine or C1 -C3 alkoxy; R4 is hydrogen, benzyl, C1 -C3 alkyl or C3 -C5 alkenyl; R5 is hydrogen, halogen, C1 -C3 alkyl or C1 -C3 alkoxy; R6 is hydrogen, C1 -C3 alkyl or C1 -C3 alkoxy or, together with R5, can be a C1 -C2 alkylenedioxy; X is an imino, optionally substituted by a benzyl or C1 -C3 alkyl, or is oxygen, sulphur, sulphinyl or sulphonyl; Y is an imino, optionally substituted by a benzyl or C1 -C3 alkyl, or is methylene or carbonyl; m and n are each independently 2, 3 or 4; and nontoxic, pharmaceutically acceptable addition salts thereof. These compounds have valuable pharmacological properties, particularly the effect of lowering heart rate and reducing the O2 requirement of the heart.
-
(2008/06/13)

Aminotetralin derivatives
This invention related to new aminotetralin derivatives of formula I STR1 wherein STR2 B is methylene or, when A is --CH2 --CH2 --, --CH=CH--, --NH--CO-- or --CH2 --CO--, B can also be carbonyl or thiocarbonyl; E is a C2 -C4 straight-chain alkylene, optionally substituted by a C1 -C3 alkyl, or is 2-hydroxy-n-propylene, 2-hydroxy-n-butylene or 3-hydroxy-n-butylene; R1 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, nitro, amino, C1 -C3 alkylamino, C1 -C3 dialkylamino, C1 -C3 alkyl, C1 -C3 alkylthio, hydroxy, C1 -C3 alkoxy or phenyl C1 -C3 alkoxy; R2 is hydrogen, chlorine, bromine, hydroxy, C1 -C3 alkoxy phenyl C1 -C3 alkoxy, or C1 -C3 alkyl or, together with R1, can be a C1 -C2 alkylenedioxy; R3 and R4 are each independently selected from hydrogen, fluorine, chlorine, bromine, C1 -C3 alkyl, hydroxy, C1 -C3 alkoxy, nitro, amino, C1 -C3 alkylamino, or C1 -C3 dialkylamino, or together can be methylenedioxy; and R5 is hydrogen, C3 -C5 alkenyl, C1 -C3 alkyl, or phenyl C1 -C3 alkyl, and nontoxic, pharmaceutically acceptable addition salts thereof which have valuable pharmacological properties, particularly a long-lasting heart rate lowering effect and the effect of reducing the O2 requirement of the heart.
-
(2008/06/13)

Benzazepine derivatives, their pharmaceutical compositions and method of use
Compounds of the formula STR1 wherein A is --CH2 --CH2 --, --CH=CH--, --NH--CO--, --CH2 --CO-- or STR2 where R7 is alkyl of 1 to 3 carbon atoms, and B is methylene, carbonyl or thiocarbonyl, or A is --CO--CO--, --N=CH--, STR3 where R8 is hydrogen or alkyl of 1 to 3 carbon atoms substituted by a phenyl, methoxyphenyl or dimethoxyphenyl, and B is methylene; E is n-alkylene of 2 to 4 carbon atoms optionally substituted by an alkyl of 1 to 3 carbon atoms, 2-hydroxy-n-propylene, 2-hydroxy-n-butylene or 3-hydroxy-n-butylene; G is n-alkylene of 1 to 5 carbon atoms optionally substituted by an alkyl of 1 to 3 carbon atoms, wherein one methylene group of an n-alkylene of 2 to 5 carbon atoms can be replaced by a carbonyl group, with the proviso that B represents a methylene or carbonyl group, or methylene-n-hydroxy-alkylene of 1 to 4 carbon atoms, where the methylene group is attached to the nitrogen atom; and R1 to R5 are simple substituents of various types; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.
-
(2008/06/13)